Driver of responses to checkpoint inhibitors suggests way to improve cancer therapy
Expansion of a diverse subset of T-cell clones influences how patients respond to immune checkpoint inhibitors (ICIs), suggesting it may be possible to predict who will benefit from the treatments. Read More
Implication of nervous system in anaphylaxis opens ways to treat severe allergic reactions
Heat-sensing neurons are key contributors to severe allergic shock reactions, according to a study in mice that points to ways to reverse life-threatening symptoms. Read More
Nasal antibody modulates inflammatory response in COVID-19 patients in small clinical trial
A nasally administered monoclonal antibody modulated inflammatory responses in COVID-19 patients in a small clinical trial. Read More
Immune homing mechanism enables targeted drug delivery to pediatric brain tumors in mice
Piggybacking on the homing mechanism that the immune system uses to direct white blood cells could enable the targeted delivery of drugs in children with brain tumors, according to research published on Thursday in Nature Materials. Read More
COVID-19 vaccine development: Public funding yielded private profits
Decades before the COVID-19 pandemic, the U.S. government invested at least $337 million into critical research that led to mRNA COVID-19 vaccines. The government also paid $31.6 billion during the pandemic for vaccine research, production, and vaccines for all Americans. Read More
Adaptive Biotechnologies Q4 revenues rise 46% on NGS test volumes
Adaptive Biotechnologies on Tuesday reported fourth-quarter revenue of $55.2 million, up 46% compared with $37.9 million in Q4 2021. Read More
Vaccine effectiveness against Omicron variants may change over time
Researchers from The Chinese University of Hong Kong and the Harvard T.H. Chan School of Public Health in Boston, Massachusetts collaborated on a case-control study and found that two vaccines were generally effective over time against severe outcomes from SARS-CoV-2 Omicron infection. The research, published February 3 in the journal JAMA Network Open, also showed that protection among older individuals was more likely to wane six months after the second dose. Read More
Study suggests immune response to anticancer checkpoint inhibitors unaffected by COVID-19 vaccination
Immune checkpoint inhibitors perform comparably in vaccinated and unvaccinated individuals, allaying concerns that injections given to protect against COVID-19 will interfere with cancer treatment. Read More
Marburg virus vaccine safe in small, first-in-human clinical trial: NIH
A study published in the Lancet on January 28 shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. Read More
Peptide suppresses inflammation in mice, spurs work to develop 1st targeted lung injury therapy
A peptide has suppressed acute lung injury (ALI) in mice harmed by bacterial infection, revealing a path to developing the first targeted medical therapy for the condition. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
